scholarly journals OC07.06: Pregnancy outcomes following multicentre clinical implementation of routine first trimester screening for preterm pre‐eclampsia in Australia

2021 ◽  
Vol 58 (S1) ◽  
pp. 22-23
Author(s):  
D. Lorber Rolnik ◽  
R. Selvaratnam ◽  
D. Wertaschnigg ◽  
S. Meagher ◽  
E. Wallace ◽  
...  
Keyword(s):  
Pregnancy Outcomes ◽  
First Trimester ◽  
First Trimester Screening ◽  
Clinical Implementation ◽  
Trimester Screening

scholarly journals Does the Thyroid-Stimulating Hormone Measured Concurrently With First Trimester Biochemical Screening Tests Predict Adverse Pregnancy Outcomes Occurring After 20 Weeks Gestation?

2014 ◽  
Vol 99 (12) ◽  
pp. E2668-E2672 ◽  
Author(s):  
Gregory S. Y. Ong ◽  
Narelle C. Hadlow ◽  
Suzanne J. Brown ◽  
Ee Mun Lim ◽  
John P. Walsh
Keyword(s):  
Thyroid Function ◽  
Pregnancy Outcomes ◽  
First Trimester ◽  
Adverse Pregnancy Outcomes ◽  
Adverse Outcomes ◽  
First Trimester Screening ◽  
Free T4 ◽  
Trimester Screening ◽  
Secondary Outcomes ◽  
Adverse Pregnancy

Context: Maternal hypothyroidism in early pregnancy is associated with adverse outcomes, but not consistently across studies. First trimester screening for chromosomal anomalies is routine in many centers and provides an opportunity to test thyroid function. Objective: To determine if thyroid function tests performed with first trimester screening predicts adverse pregnancy outcomes. Design, Participants and Setting: A cohort study of 2411 women in Western Australia with singleton pregnancies attending first trimester screening between 9 and 14 weeks gestation. Outcome Measures: We evaluated the association between TSH, free T4, free T3, thyroid antibodies, free beta human chorionic gonadotrophin (β-hCG) and pregnancy associated plasma protein A (PAPP-A) with a composite of adverse pregnancy events as the primary outcome. Secondary outcomes included placenta previa, placental abruption, pre-eclampsia, pregnancy loss after 20 weeks gestation, threatened preterm labor, preterm birth, small size for gestational age, neonatal death, and birth defects. Results: TSH exceeded the 97.5th percentile for the first trimester (2.15 mU/L) in 133 (5.5%) women, including 22 (1%) with TSH above the nonpregnant reference range (4 mU/L) and 5 (0.2%) above 10 mU/L. Adverse outcomes occurred in 327 women (15%). TSH and free T4 did not differ significantly between women with or without adverse pregnancy events. On the multivariate analysis, neither maternal TSH >2.15 mU/L nor TSH as a continuous variable predicted primary or secondary outcomes. Conclusion: Testing maternal TSH as part of first trimester screening does not predict adverse pregnancy outcomes. This may be because in the community setting, mainly mild abnormalities in thyroid function are detected.

scholarly journals Cell-free DNA Testing: Where are We now?

2016 ◽  
Vol 10 (2) ◽  
pp. 172-177
Author(s):  
Gokhan Goynumer ◽  
Cihat Sen ◽  
Olus Api ◽  
Murat Yayla
Keyword(s):  
Maternal Age ◽  
Detection Rate ◽  
False Positive Rate ◽  
First Trimester ◽  
First Trimester Screening ◽  
Dna Testing ◽  
Clinical Implementation ◽  
Free Dna ◽  
Positive Rate ◽  
Trimester Screening

ABSTRACT Prenatal screening for fetal aneuploidies has been focused on mainly Down syndrome in the last 40 years. The method of screening has changed from maternal age in the 1970s, with a detection rate of 30 and 5% false positive rate (FPR), to a combination of maternal age and second-trimester serum biochemical markers (triple test and quadruple test) in the 1980s and 1990s, with 60 to 75% detection rate and 5% false positive rate (FPR). Following this, the era of first trimester screening for Down syndrome has started with the clinical implementation of fetal nuchal translucency screening. The combination of maternal age, NT thickness and serum free beta-human chorionic gonadotropin (â-hCG) and pregnancy-associated plasma protein A (PAPP-A) in the first trimester has yielded a 90% detection rate with a 5% FPR. Starting from the year 2008, studies have shown that the performance of screening may be improved by analysis of cell-free deoxyribonucleic acid (DNA) (cfDNA) in maternal blood. Several studies in the last few years have reported the clinical validation of cell free fetal DNA test in the maternal serum in screening for trisomies 21, 18, and 13 and sex chromosome aneuploidies. Its widespread use is limited by the relatively high cost of the test and the lack of consensus about the optimal way for its clinical implementation. Until the optimal way of incorporating cfDNA into the clinical practice gets identified, it would be wise not to substitute cfDNA testing in place of first-trimester screening for fetal defects and other major complications of pregnancy. Furthermore, it would be preferable for clinicians managing individual patients not to counsel them for their result as positive or negative, rather the clinicians should use the risk estimate from the first-line method of screening as the prior risk and modify this by the appropriate positive or negative likelihood ratio from the cfDNA test. How to cite this article Sen C, Api O, Yayla M, Goynumer G. Cell-free DNA Testing: Where are We now? Donald School J Ultrasound Obstet Gynecol 2016;10(2):172-177.

Trends in early prenatal screening for chromosomal abnormalities and congenital malformations in Russia in 2018

2020 ◽  
pp. 76-78
Author(s):  
Е.А. Калашникова ◽  
Е.Н. Андреева ◽  
П.А. Голошубов ◽  
Н.О. Одегова ◽  
Е.В. Юдина ◽  
...  
Keyword(s):  
Reference Values ◽  
Congenital Malformations ◽  
Prenatal Screening ◽  
Chromosomal Abnormalities ◽  
First Trimester ◽  
First Trimester Screening ◽  
Trimester Screening ◽  
Overall Effectiveness ◽  
Regions Of Russia

В ходе анализа результатов раннего пренатального скрининга (РПС) в России за 2018 г. (Аудит-2019) дана оценка качества мероприятий, общей эффективности и тенденций развития системы РПС в субъектах РФ посредством сравнения рассчитанных основных организационных, методологических и интегральных показателей с международными референтными значениями. In the course of analyzing the results of early prenatal combined first-trimester screening (FTS) in Russia for 2018 (Audit-2019) the assessment of the quality of measures, the overall effectiveness and trends in the development of the FTS system in the regions of Russia. They are presented by comparing the calculated main organizational, methodological and integral indicators with international reference values.

Sign in / Sign up

Export Citation Format

Share Document